MX2011011950A - Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas. - Google Patents

Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.

Info

Publication number
MX2011011950A
MX2011011950A MX2011011950A MX2011011950A MX2011011950A MX 2011011950 A MX2011011950 A MX 2011011950A MX 2011011950 A MX2011011950 A MX 2011011950A MX 2011011950 A MX2011011950 A MX 2011011950A MX 2011011950 A MX2011011950 A MX 2011011950A
Authority
MX
Mexico
Prior art keywords
methods
dexmedetomidine compositions
sublingual
sublingual dexmedetomidine
compositions
Prior art date
Application number
MX2011011950A
Other languages
English (en)
Spanish (es)
Inventor
Geraldine Anne Henwood
Christopher Thomas Sharr
John Joseph Koleng Jr
Randall Jerome Mack
Original Assignee
Recro Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43085620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011011950(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recro Pharma Inc filed Critical Recro Pharma Inc
Publication of MX2011011950A publication Critical patent/MX2011011950A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00Anatomical parts of the body
    • A61M2210/06Head
    • A61M2210/0625Mouth

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2011011950A 2009-05-15 2010-05-17 Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas. MX2011011950A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17873009P 2009-05-15 2009-05-15
PCT/US2010/035136 WO2010132882A2 (en) 2009-05-15 2010-05-17 Sublingual dexmedetomidine compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2011011950A true MX2011011950A (es) 2012-02-21

Family

ID=43085620

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011950A MX2011011950A (es) 2009-05-15 2010-05-17 Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.

Country Status (21)

Country Link
US (1) US20110021588A1 (https=)
EP (2) EP3305281A1 (https=)
JP (2) JP6172938B2 (https=)
KR (1) KR101859486B1 (https=)
CN (2) CN106511273A (https=)
AU (1) AU2010248776B2 (https=)
BR (1) BRPI1010567A2 (https=)
CA (1) CA2762107A1 (https=)
CL (1) CL2011002858A1 (https=)
CO (1) CO6460767A2 (https=)
CR (1) CR20110596A (https=)
DO (1) DOP2011000354A (https=)
EC (1) ECSP11011459A (https=)
HN (1) HN2011003011A (https=)
IL (1) IL216159A (https=)
MX (1) MX2011011950A (https=)
NZ (1) NZ596976A (https=)
PE (1) PE20120713A1 (https=)
RU (1) RU2572692C2 (https=)
SG (1) SG175979A1 (https=)
WO (1) WO2010132882A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
AU2012352528B9 (en) * 2011-12-11 2017-11-02 Baudax Bio, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
CA2865593A1 (en) * 2012-02-27 2013-09-06 Eye Therapies Llc Compositions and methods for the treatment of migraine
DK2906213T3 (en) * 2012-10-15 2018-02-19 Orion Corp VETERINARY PROCEDURE FOR RELIEFING NOISE SENSITIVITY
EP2792352A1 (en) * 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
US20150273215A1 (en) * 2014-03-26 2015-10-01 Pacesetter, Inc. Systems and methods for assessment of pain and other parameters during trial neurostimulation
KR101827980B1 (ko) 2013-10-07 2018-02-13 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
CA2924233C (en) 2013-10-07 2018-10-23 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
BR112016006848A2 (pt) * 2013-10-07 2017-08-01 Teikoku Pharma Usa Inc métodos e composições para distribuição transdérmica de uma quantidade não sedativa de dexmedetomidina
RU2557882C1 (ru) * 2014-07-08 2015-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО АГМА Минздрава России) Способ проведения премедикации при плановом хирургическом лечении
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
TWI764951B (zh) 2016-10-31 2022-05-21 美商帝國製藥美國股份有限公司 用於處理疼痛之右美托咪啶經皮遞送裝置
SI3554501T1 (sl) * 2016-12-13 2021-09-30 Orion Corporation Deksmedetomidin ali medetomidin za uporabo pri zdravljenju ločitvene tesnobe pri hišnih živalih
KR102793584B1 (ko) * 2016-12-31 2025-04-09 바이오엑셀 테라퓨틱스 인코포레이티드 불안의 치료를 위한 설하 덱스메데토미딘의 용도
PL3813802T3 (pl) * 2018-06-27 2025-04-22 Bioxcel Therapeutics, Inc. Formulacje błony zawierające deksmedetomidynę i sposoby ich wytwarzania
US12472158B2 (en) 2019-02-27 2025-11-18 Vanderbilt University Methods of treating trigeminal nerve pain
CN116474219A (zh) * 2019-06-28 2023-07-25 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
EP3999058A4 (en) * 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. NON-SEDATIVE DEXMEDETOMIDINE-BASED TREATMENT REGIMEN
CN118948739A (zh) * 2020-06-08 2024-11-15 四川普锐特药业有限公司 右美托咪定滴鼻剂或鼻喷剂在助眠药物制备中的应用
US20220031664A1 (en) * 2020-07-28 2022-02-03 Melt Pharmaceuticals, Inc. Pharmaceutical compositions comprising antiemetics and alpha-2-adrenergic receptor agonists and methods of using the same for anesthesiological applications
WO2024055042A1 (en) * 2022-09-11 2024-03-14 Bioxcel Therapeutics, Inc. Methods for treating agitation in community settings
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
CN118542852B (zh) * 2024-07-30 2024-10-01 山东则正医药技术有限公司 包含经口给药的右美托咪定舌下膜组合物及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5217718A (en) * 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) * 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
WO1992010228A1 (en) * 1990-12-05 1992-06-25 The General Hospital Corporation Devices for treating pulmonary vasoconstriction and asthma
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
US5571840A (en) * 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
US5713907A (en) * 1995-07-20 1998-02-03 Endotex Interventional Systems, Inc. Apparatus and method for dilating a lumen and for inserting an intraluminal graft
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
NZ510771A (en) * 1998-10-02 2003-08-29 3M Innovative Properties Co Mucosal originated drug delivery systems
US7001609B1 (en) * 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
GB9913677D0 (en) * 1999-06-11 1999-08-11 Imperial College Formulation
AUPR184500A0 (en) * 2000-12-01 2001-01-04 Drug Delivery Solutions Pty Ltd Dispensing device
WO2002089794A1 (en) * 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
WO2002094238A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of anti-migraine compounds through an inhalation route
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
WO2006105205A1 (en) * 2005-03-29 2006-10-05 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
RU2432950C2 (ru) * 2006-01-25 2011-11-10 Инсис Терапьютикс Инк. Подъязычный спрей на основе фентанила
PT1986642E (pt) * 2006-02-13 2014-01-30 Orient Pharma Samoa Co Ltd Combinação de agonista do receptor alfa-2 (clonidina) e um agente antimuscarínico (oxibutinina) para o tratamento de sialorreia
WO2008003093A2 (en) * 2006-06-29 2008-01-03 Questcor Pharmaceuticals, Inc. Pharmaceutical compositions and related methods of treatment
CN101057830A (zh) * 2007-05-10 2007-10-24 北京天川军威医药技术开发有限公司 盐酸纳洛酮舌下喷雾给药系统或组合物及其制备方法

Also Published As

Publication number Publication date
CR20110596A (es) 2012-03-26
CO6460767A2 (es) 2012-06-15
JP2016029055A (ja) 2016-03-03
WO2010132882A8 (en) 2011-12-29
EP3305281A1 (en) 2018-04-11
IL216159A0 (en) 2012-01-31
DOP2011000354A (es) 2012-07-15
KR20120008058A (ko) 2012-01-25
WO2010132882A2 (en) 2010-11-18
ECSP11011459A (es) 2012-01-31
JP6172938B2 (ja) 2017-08-02
IL216159A (en) 2015-10-29
CL2011002858A1 (es) 2012-06-22
EP2429521A2 (en) 2012-03-21
CA2762107A1 (en) 2010-11-18
SG175979A1 (en) 2011-12-29
AU2010248776B2 (en) 2013-06-06
EP2429521B1 (en) 2017-10-18
WO2010132882A3 (en) 2011-03-31
US20110021588A1 (en) 2011-01-27
RU2011151059A (ru) 2013-06-20
CN102639131A (zh) 2012-08-15
NZ596976A (en) 2014-05-30
HN2011003011A (es) 2014-12-01
BRPI1010567A2 (pt) 2016-03-15
JP2012526854A (ja) 2012-11-01
RU2572692C2 (ru) 2016-01-20
AU2010248776A1 (en) 2012-01-12
PE20120713A1 (es) 2012-07-08
EP2429521A4 (en) 2013-08-21
CN106511273A (zh) 2017-03-22
KR101859486B1 (ko) 2018-06-28

Similar Documents

Publication Publication Date Title
MX2011011950A (es) Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.
MX2012007933A (es) Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso.
MX2011007930A (es) Conjugados de insulina cristalina.
MX2009012690A (es) Composiciones, metodos, dispositivos y sistemas para el cuidado bucal.
WO2009089494A3 (en) Pharmaceutical compositions
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
GB0920703D0 (en) Compositions containing satiogens and methods of use
MX338489B (es) Derivados de hidantoina utiles como inhibidores de kv3.
MX2011003473A (es) Composiciones para el cuidado bucal.
MY160041A (en) Compositions and methods for treating parasitic infections
IN2012DN00624A (https=)
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
WO2009114703A3 (en) Combination therapy for the treatment of cancer
TN2012000059A1 (en) Compositions comprising tramadol and celecoxib in the treatment of pain
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2010002667A (es) Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
PH12012501389A1 (en) Hedgehog inhibitors
ZA201008160B (en) Compositions for the treatment of hair loss
HK1215391A1 (zh) 使用胎盘细胞外基质治疗口腔病变
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
MY157007A (en) Novel possibility of controlling giardiosis
MX2011013324A (es) Uso de derivados de oxindol sustituidos para el tratamiento y profilaxis del dolor.
EP2597949A4 (en) SUBMIKROMETERZUSAMMENSETZUNGEN
PL2375912T3 (pl) Kompozycje i sposoby leczenia uczucia dyskomfortu gardła

Legal Events

Date Code Title Description
FG Grant or registration